ESR1 and Alzheimer disease: Although definitive mechanisms underlying the aforementioned observations remain unresolved, some reports suggest that declines in ERα agonism during the menopausal transition is a major contributor to female-dominant cognitive declines [71-73], which is further supported by the fact that females receiving estrogen replacement therapies have decreased risk for onset and/or development of AD [74].